Eila Life Sciences Profile
Key Indicators
- Authorised Capital ₹ 0.10 M
- Paid Up Capital ₹ 0.10 M
- Company Age 8 Year, 3 Months
- Last Filing with ROC 31 Mar 2023
- Revenue Growth -27.13%
- Profit Growth -68.64%
- Ebitda -79.08%
- Net Worth 8.50%
- Total Assets -50.26%
About Eila Life Sciences
Eila Life Sciences Private Limited (ELSPL) is a Private Limited Indian Non-Government Company incorporated in India on 29 October 2016 (Eight years and three months 3 days old ). Its registered office is in Hyderabad, Telangana, India.
The Company is engaged in the Life Sciences Industry.
The Company's status is Active, and it has filed its Annual Returns and Financial Statements up until 31 March 2023. It's a company limited by shares with an authorized capital of Rs 0.10 M and a paid-up capital of Rs 0.10 M, as per Ministry of Corporate Affairs (MCA) records.
Raunak Soman and Dhruv Soman serve as directors at the Company.
Company Details
- Location
Hyderabad, Telangana, India
- Telephone
+91-XXXXXXXXXX
- Email Address
- Website
-
- Social Media-
Corporate Identity Details
- CIN/LLPIN
U24304TG2016PTC112681
- Company No.
112681
- Company Classification
Private Limited Indian Non-Government Company
- Incorporation Date
29 Oct 2016
- Date of AGM
27 Sep 2023
- Date of Balance Sheet
31 Mar 2023
- Listing Status
Unlisted
- ROC Code
Roc Hyderabad
Industry
Who are the key members and board of directors at Eila Life Sciences?
Board Members (2)
| Name | Designation | Appointment Date | Status |
|---|---|---|---|
Raunak Soman  | Director | 29-Oct-2016 | Current |
| Dhruv Soman | Director | 29-Oct-2016 | Current |
Financial Performance of Eila Life Sciences.
Eila Life Sciences Private Limited, for the financial year ended 2023, experienced significant reduction in revenue, with a 27.13% decrease. The company also saw a substantial fall in profitability, with a 68.64% decrease in profit. The company's net worth moved up by a moderate rise of 8.5%.
- Key Matrics
- Balance Sheet
- Profit and Loss
- Cash Flow
- Ratios
| Metrics |
| (FY 2022) | (FY 2021) | (FY 2020) | (FY 2019) | ||
|---|---|---|---|---|---|---|---|
| Total Revenue |
| ||||||
| Revenue from Operations |
| ||||||
| Total Assets |
| ||||||
| Profit or Loss |
| ||||||
| Net Worth |
| ||||||
| EBITDA |
|
What is the Ownership and Shareholding Structure of Eila Life Sciences?
In 2023, Eila Life Sciences had a promoter holding of 100.00%. Access key insights, ownership, including shareholding patterns, funding, foreign investors, KMP remuneration, group structure, and overseas investments.
Related Corporates (Common Directorship)
Sanzyme Private LimitedRaunak Soman and Dhruv Soman are mutual person
Sanzyme Biologics Private LimitedRaunak Soman and Dhruv Soman are mutual person
Charges (Loans)
There are no open charges registered against the company as per our records.
How Many Employees Work at Eila Life Sciences?
Unlock and access historical data on people associated with Eila Life Sciences, such as employment history, contributions to the Employees' Provident Fund Organization (EPFO), and related information.
Deals i
Gain comprehensive insights into the Deals and Valuation data of Eila Life Sciences, offering detailed information on various transactions, including security allotment data. Explore the intricate details of financial agreements, mergers, acquisitions, divestitures, and strategic partnerships that have shaped Eila Life Sciences's trajectory.
Rating
Access the credit rating data, providing valuable insights into the company's creditworthiness and financial stability. Explore assessments from leading credit rating agencies, evaluating factors such as debt obligations, liquidity, profitability, and overall financial health.
Alerts
Stay informed about regulatory alerts and litigation involving and associated companies. Receive timely updates on legal proceedings, regulatory changes, and compliance issues that may impact the company's operations, reputation, and financial performance. Monitor litigation involving subsidiaries, joint ventures, and other affiliated entities to assess potential risks and liabilities.